CD8A and type 1 diabetes mellitus: We recently found that repeated treatment of APL of mInsB5–14 with histidine to phenylalanine substitution at the potential TCR contact site (p6) prevents T1D via selectively expanding a tiny population of CD8+CD25+Foxp3+ regulatory T cells in humanized NOD mice (14).